Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: results + 591 + web  Related to the article below (Last Update: 8/5/2008)

Vion Reports 2008 Second Quarter and Six-Month Results
Earthtimes (press release), UK -
To participate in the conference call, please dial (800) 591-6930 in the US ((617) 614-4908 for international callers) at least 15 minutes before the start ...VION
Bridgeline Software to Report Third Quarter Fiscal 2008 Financial ...
CNNMoney.com (press release) -
To listen to the conference call please dial (877) 591-4953 a few minutes prior to the scheduled start time (international callers please dial (719) ...BLSW
eResearchTechnology Reports Second Quarter 2008 Results
IT News Online, India -
This call is being webcast by Thomson Financial and can be accessed at eRT's web site at . The webcast may also be accessed at Thomson's Institutional ...
Archer Daniels Midland Reports Annual Results
CNNMoney.com (press release) - 6 minutes ago
To listen by telephone, dial 800-591-6930 or 617-614-4908; the access code is 64043411. Replay of the call will be available beginning August 5, 2008, ...ADM
Fraser Papers Announces Second Quarter Financial Results
MarketWatch - Jul 31, 2008
The conference call can also be accessed via web cast on the Fraser Papers web site at www.fraserpapers.com. Fraser Papers is an integrated specialty paper ...TSE:FPS
Federal Realty Investment Trust Announces Second Quarter 2008 ...
PR Newswire (press release), NY - Jul 30, 2008
Financial Results In second quarter 2008, Federal Realty generated FFO of $56.7 million, or $0.96 per diluted share. This compares to FFO of $51.9 million, ...FRT
Sonic Automotive, Inc. Announces Second Quarter Results
Earthtimes (press release), UK - Jul 29, 2008
Sonic can be reached on the Web at www.sonicautomotive.com Included herein are forward-looking statements, including statements with respect to July ...
CONSOL Energy Reports Earnings for Second Quarter 2008 Earthtimes (press release)
all 376 news articles »  SAH - CNX
Newtek Business Services to Announce Second Quarter 2008 Financial ...
CNNMoney.com (press release) - Jul 23, 2008
The live conference call can be accessed by dialing (877) 591-4951 (domestic) or (719) 325-4862 (international). A live audio webcast of the call and the ...NEWT
CRM Holdings, Ltd. Announces Conference Call to Discuss Second ...
CNNMoney.com (press release) - Jul 23, 2008
To participate in the event by telephone, please dial 877-591-4952 five to 10 minutes prior to the start time (to allow time for registration) and reference ...CRMH
New Flyer To Announce 2008 Second Quarter Results August 5th and ...
FOXBusiness - Jul 23, 2008
The call-in number for listeners is 800-591-7539 or 416-644-3428. A live audio feed of the call will also be available at: ...TSE:NFI.UN - OTC:CMTX
Source: Google News

Responses to Unsolicited Patient E-mail Requests for Medical Advice on the World Wide Web -
G Eysenbach, TL Diepgen - JAMA, 1998 - Am Med Assoc
... Another clinical problem might produce different results. ... forthcoming, we suggest
that medical institutions that maintain Web sites develop ... 1995;89:579-591. ...

Self-similarity in World Wide Web traffic: evidence and possiblecauses -
ME Crovella, A Bestavros - Networking, IEEE/ACM Transactions on, 1997 - ieeexplore.ieee.org
... to modify a WWW browser so as to log all user accesses to the Web. ... transfers are
short [6]?means that such smoothing has little effect on our results. ... 591 ...

Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and … -
ST Shi, GY Yang, LD Wang, Z Xue, B Feng, W Ding, … - Carcinogenesis, 1999 - Oxford Univ Press
... 4, 591-597, April 1999 ? 1999 Oxford University Press Role of p53 gene mutations
in human esophageal carcinogenesis: results from immunohistochemical and ...

Toward the semantic geospatial web -
MJ Egenhofer - Proceedings of the 10th ACM international symposium on …, 2002 - portal.acm.org
... and the evaluation of the retrieval results based on ... Copyright 2002 ACM
1-58113-591-2/02/0011 ... While the Semantic Web approaches provide generic frameworks ...

IGroup: presenting web image search results in semantic clusters -
S Wang, F Jing, J He, Q Du, L Zhang - Proceedings of the SIGCHI conference on Human factors in …, 2007 - portal.acm.org
... of IGroup avoids the randomness of related images, thus ensures more perceived
relevance of the search results. ... CHI 2007 Proceedings ? Web Usability ... 591 ...

[BOOK] The Handbook of Data Mining -
N Ye - 2003 - books.google.com
... Standards 457 Semantic Web 457 Data Web 458 Other Web Services 458 ... in Contact Maps
589 Pruning and Integration 590 Experimental Results 591 Future Directions ...

[PDF] Is It Correct?-Towards Web-Based Evaluation of Automatic Natural Language Phrase Generation -
CS Montero, K Araki - Proceedings of the COLING/ACL on Interactive presentation …, 2006 - acl.ldc.upenn.edu
... to reflect n-grams whose appearance on the Web is significant even ... Table 2 contains
the results. There were 591 different phrases generated, from which 80 were ...

Managing semantic content for the Web -
A Sheth, C Bertram, D Avant, B Hammond, K Kochut, … - Internet Computing, IEEE, 2002 - ieeexplore.ieee.org
... I word collocations and frequencies; I a Web site?s trustworthiness, importance,
and popularity; and I restriction of results to a particular category using ...

pTARGET: a web server for predicting protein subcellular localization -
C Guda - Nucleic Acids Research, 2006 - Oxford Univ Press
... 518 591 7155; Fax: +1 518 591 7151; Email ... The pTARGET web server enables prediction
of nine distinct ... PreCalcDB, to store pre-computed prediction results for all ...

[PDF] SNPAnalyzer: Web-Based Workbench for the SNPs Analysis -
J Yoo, B Seo, Y Kim - Genome Informatics, 2003 - jsbi.org
... 591 SNPAnalyzer: Web-Based Workbench for the SNPs Analysis ... All the analysis results
are displayed in user-friendly format of tables, graphs, or maps. ...

Source: Google Scholar

Preliminary Results For Phase III Study Evaluating CellCept In Lupus Nephritis
Aspreva Pharmaceuticals Corporation and Roche today released preliminary results for a clinical phase III trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.

Although response rates were similar in both arms, the trial did not meet its primary objective of demonstrating that MMF was superior to IVC in inducing treatment response in this disease. The results relate to the induction phase of this study, which was designed to measure treatment response in patients after 24 weeks of induction therapy with 185 patients in the MMF arm and 185 in the IVC arm.
The results indicate similar treatment responses were observed, with 56.2% in the MMF arm and 53% in the IVC arm. Additional analyses are ongoing to determine the potential for regulatory submission, and Aspreva plans to present the final results at an appropriate scientific forum in the future.

Based on preliminary analysis, it appears that, in general, the adverse events experienced by patients in both arms of the study are consistent with those observed in lupus nephritis patients receiving immunosuppressive therapy. Overall incidence of adverse events was comparable in both treatment arms.

About Lupus Nephritis

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered life threatening but rare, is the most serious manifestation of the disease, which, if left untreated, can lead to kidney failure, requiring dialysis and potentially death. It is a complicated disease as patients typically fluctuate between periods of intense disease activity when the patient's own immune system is actively attacking and causing damage in their kidney, interspersed with periods of remission. Clinicians estimate that one third to one half of lupus patients have lupus nephritis. There has been no new approved treatment for SLE or lupus nephritis in the United States in over forty years. Current treatments involve the off-label use of existing cancer drugs such as cyclophosphamide, steroids, and other immunosuppressant drugs such as azathioprine.
About CellCept

CellCept is Roche's leading immunosuppressant or "anti-rejection" drug. It is used in combination with other immunosuppressive drugs (cyclosporine and corticosteroids) for the prevention of rejection in patients receiving heart, kidney and liver transplants. CellCept was first approved for use in combination therapy for the prevention of acute organ rejection in kidney transplantation in 1995 and has since been approved worldwide for prevention of organ rejection in adult kidney, heart and liver transplantation. This therapeutic success in the prevention of organ rejection in adult kidney, heart and liver transplantation represents 11 years of clinical experience and patient benefits, including reduced toxicities and prolonged graft and patient survival. In July 2003, Aspreva signed a collaboration agreement with Roche for the exclusive worldwide rights (excluding Japan) to develop and, upon regulatory approval, commercialise CellCept for all autoimmune disease applications. It is important to note that CellCept has not been approved by the FDA for the treatment of any autoimmune disease.

About Aspreva Pharmaceuticals

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercialising evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV". Learn more at http://www.aspreva.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at http://www.roche.com.
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.